Viable
Adaptimmune, after bringing cell therapy to market, questions viability and defunds 2 preclinical programs
Adaptimmune, Tecelra, Viable, Market, Solid Neoplasm, cellular targeting
Pfizer Terminates Hemophilia A Gene Therapy Partnership with Sangamo, Citing Commercial Viability Concerns
Pfizer, Sangamo Therapeutics, Hemophilia A, Gene Therapy, Commercial Viability, Partnership Termination